DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award
Defense Health Agency Contracting Activity - DHACA
Free. Verify your email, then we send one reminder only.
- Posted
- May 4, 2026
- Amount
- Program total $12M
- Closes
- Sep 30, 2026 (in 13 days)
Similar opportunities open now
- DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 13 days
- DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 13 days
- DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 13 days
- DoW Autism Clinical Trial AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 35 days
- DoW Autism Career Development AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 35 days
Classification and identifiers
- Solicitation number
- HT942526ALSRPTDA
- Assistance listing (CFDA)
- 12.420
Amount
Program total $12M
Who can apply
About this opportunity
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology. Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including...